Recent news on Epogen

CHMP backs Roche's Mircera  -  25 May 2007
Pharma Times (subscription),...while rivals such as Amgen's Epogen (epoetin alfa) and Johnson & Johnson's Procrit (epoetin alfa) can be dosed up to three times a week.

JAMA Editorial Raps For-Profit Dialysis Centers Over Dosing of ...  -  May 9, 2007
Biologic Drug Report,Big dialysis chains like DaVita derive a quarter of their earnings from reimbursement for Epogen, and DaVita in 2005 reported "our agreement with Amgen

5% Reduction in Smoking Could Save 100 Million Lives  -  May 21, 2007
DentalPlans.com,If approved, Mircera would compete with Amgen's Aranesp and Epogen and Johnson and Johnson's Procrit. An FDA advisory panel last week recommended warning

Amgen Keeps Low Profile As Bad News Piles Up  -  May 18, 2007
Investor's Business Daily (subscription)Amgen's stock is getting beat up because it relies on Aranesp and Epogen for almost half its revenue. In 2006, the two drugs accounted for $6.6 billion of

US delays approval of anemia drug from Roche  -  May 19, 2007
International Herald Tribune,Amgen's Epogen, which is sold only for dialysis use in the United States, had sales last year of $2.5 billion. Medicare, which pays for most dialysis,

Amgen knocked back as EPO competition looms  -  May 17, 2007
BiopharmaReporter.com,Amgen is trying to prevent competition to Epogen and its other erythropoietin-based anaemia drug Aranesp (darbepoetin alfa) in the US, which together

Court Turns Down Amgen Patent Appeal  -  May 14, 2007
WTOP,Amgen received $2.5 billion in revenue from Epogen sales in 2006. The case is Amgen Inc. v. Hoechst Marion Roussel Inc., 06-1291.

Amgen shares extend losses following FDA panel  -  May 11, 2007
MarketWatchAmgen licensed several rights for Epogen to Johnson & Johnson in the 1980s, which has since marketed it under the name Procrit. The injectable drugs are

Justices Turn Down Drug Patent Dispute  -  May 14, 2007
New York Times,Typically, United States appeals courts consider issues of law, rather than fact. Last year, Amgen received $2.5 billion in revenue from Epogen sales.

Supreme Court Declines to Hear Appeal in Patent Fight Over ...  -  May 14, 2007
Biologic Drug Report,Amgen has been trying to block Sanofi-Aventis and Shire PLC from offering competing drugs to Epogen, which is used as an anemia treatment for cancer and

Amgen Hit by FDA Panel Ruling  -  May 10, 2007
TheStreet.comAranesp, Procrit and Epogen are approved to treat anemia in patients with chronic kidney failure and in cancer patients whose anemia is caused by

FDA Delays Approval of Roche Anemia Drug  -  May 18, 2007
Houston Chronicle,...whose stock has dropped more than 15 percent in the last week due to safety concerns over treatments Aranesp and Epogen, which account for nearly half

» FDA Stops Short of Approving Roche Drug «  -  May 18, 2007
Examiner.comNews), whose stock dropped more than 15 percent in the last week due to safety concerns over treatments Aranesp and Epogen, which account for nearly

Analysis: Street mixed on Amgen  -  Apr 24, 2007
Science Daily (press release)Sharer emphasized the safety of Aranesp and EPOGEN, saying, "We are confident ESAs, including Aranesp and EPOGEN, maintain a favorable benefit/risk profile

Epogen – Overuse Dangerous  -  Apr 19, 2007
MedIndia,Today the result of the study funded by the American government show that a higher dosage of Epogen, the recommended medicine for anemia causes deadly side

Study: Some Clinics Profit From Heavier Epogen Doses  -  Apr 18, 2007
International News Service,Apr. 18--For-profit dialysis chains in the United States give patients larger doses of the expensive antianemia drug Epogen compared to nonprofit clinics,

New Research Cautions On The Overuse Of Anaemia Drug Epogen  -  Apr 18, 2007
All Headline NewsChicago, IL (AHN) - According to a study funded by the US government, for-profit dialysis centers tend to prescribe Amgen Inc.'s anemia drug Epogen at

Source: Charles H. Johnson & Associates  -  Apr 24, 2007
Primenewswire (press release),The Complaint alleges that Amgen, a biotechnology company that makes and sells Epogen and Aranesp, types of drugs which encourage the creation of

Study Critical of Epogen Overuse  -  Apr 17, 2007
Los Angeles Business Journal (subscription),The study conducted by the Medical Technology and Practice Patterns Institute, a nonprofit health-care study group, found that the sale of Amgen’s Epogen

Red and White Results at Amgen  -  Apr 24, 2007
Motley FoolThe compound names have also grown, as Amgen has been able to expand the patent expiration horizon on its original Neupogen (white blood cells) and Epogen

In Line Earnings for Amgen  -  Apr 24, 2007
Briefing.com,Sales of Anemia drugs Arnesp and Epogen increased 14.6% to $1.02 billion and 3% to $625 million, respectively. US Arnesp sales increased at a slower rate of

Medicare Payment Formula Results In Some For-Profit Dialysis ...  -  Apr 20, 2007
Medical News Today (press release),For-profit dialysis centers administer higher and more doses of the anemia medication Epogen, manufactured by Amgen, to kidney disease patients than

Amgen earnings on the rise as Aranesp sales still grow  -  Apr 24, 2007
Pharma Times (subscription),Sales growth was once again driven by anaemia drug Aranesp (darbepoetin alfa) which increased 14% to just over $1.11 billion, while Epogen (epoetin alfa)

Amgen Posts In-Line Q1 Earnings  -  Apr 24, 2007
Seeking Alpha,The company plans to cut expenses and adjust revenue forecasts because sales of anemia drugs Aranesp and Epogen are likely to drop now that clinical studies

Dosing For Dollars  -  Apr 17, 2007
Forbes,Large, for-profit dialysis chains administered significantly more of Amgen's blockbuster anti-anemia drug Epogen than did not-for-profit dialysis centers,

Congress Should Revise Medicare Payments for Anemia Drug, Stark Writes  -  Apr 20, 2007
Kaiser network.org,Congress should revise Medicare reimbursements for the anemia medication Epogen, manufactured by Amgen, to eliminate financial incentives for dialysis

Amgen's per-share profit seen rising 19%  -  Apr 23, 2007
MarketWatchAranesp and its earlier, shorter-acting version, Epogen, contributed $6.63 billion, or 48%, to Amgen's revenue in 2006.

Payments may promote drug's overuse  -  Apr 17, 2007
Chicago Sun-Times,The drug is Epogen, and Medicare pays more for it than any other single drug: $2 billion in 2005. For-profit dialysis chains say the drug accounts for up to

Popular Anemia Drug Dodges The Dagger  -  Apr 23, 2007
MedIndia,Aranesp, along with Epogen from Amgen and Procrit from Johnson & Johnson, are used by nearly a million Americans a year, mainly to treat anemia from kidney

Risky Anemia Drug A $2 Billion Medicare Expense  -  Apr 17, 2007
6abc.com,Epogen is approved by the Food and Drug Administration to prevent blood transfusions in patients suffering from anemia, which can accompany kidney failure.

Amgen shares gain on Aranesp study results  -  Apr 19, 2007
MarketWatchAranesp and its earlier, shorter-acting version, Epogen, contributed $6.63 billion, or 48%, to Amgen's revenue in 2006. Amgen licensed several rights for

Amgen and J&J Funnel Tax Dollars Through Kidney and Cancer Patients  -  Apr 17, 2007
Lawyers and Settlements,Amgen manufactures and markets darbepoetin as Aranesp, and epoetin is sold under the names Procrit and Epogen. But Procrit is distributed by Ortho Biotech

Facing Reality on Follow-On Biologics  -  Apr 23, 2007
American Enterprise Institute,It had nothing to say about biologics like Epogen, Procrit, and Aranesp for anemia; Enbrel and Remicade for rheumatoid arthritis; and Avastin and Herceptin

Stull, Stull & Brody Announces Class Action on Behalf of ...  -  Apr 18, 2007
Web Services Journal,Amgen, the largest biotechnology company in the world, makes and sells Epogen and Aranesp, erythropoiesis-stimulating agents, a type of drug which

Lawmakers Go After Amgen and J&J Over Off-Label Sales of Anemia Drugs  -  Apr 22, 2007
Lawyers and Settlements,The drugs at issue include Aranesp, the brand name for darbepoetin, and Epogen and Procrit, the brand names for epoetin. Amgen manufactures all three drugs,

Study Supports Use of Anemia Drug From Amgen  -  Apr 19, 2007
New York Times,Aranesp and Epogen together accounted for $6.6 billion of Amgen’s $14.3 billion in 2006 revenues. But some of the evidence suggesting harmful side effects,

Amgen Says Aranesp's Death Risk No Higher in Chemo (Update5)  -  Apr 19, 2007
BloombergAmgen's Aranesp and an older version, Epogen, and similar anemia medications, including Johnson & Johnson's Procrit, have come under scrutiny from lawmakers

Flawed Medicare Plan Promotes Use of Dangerous Anemia Drug  -  Apr 17, 2007
Wired NewsBecause Medicare pays hospitals extra for using Epogen, an anemia drug linked to increases in heart attacks, strokes and death, for-profit medical centers

Amgen study shows no increased Aranesp death risk  -  Apr 19, 2007
Globe and Mail,Aranesp had sales of about $4.1-billion (US) last year, and along with its predecessor Epogen accounted for roughly half of Amgen's sales.

UPDATE 1-Amgen study shows no increased Aranesp death risk  -  Apr 19, 2007
ReutersAranesp had sales of about $4.1 billion last year, and along with its predecessor Epogen accounted for roughly half of Amgen's sales.

Source: Schatz Nobel Izard, PC  -  Apr 17, 2007
Primenewswire (press release),The Complaint alleges that Amgen, a biotechnology company that makes and sells Epogen and Aranesp, erythropoiesis-stimulating agents, a type of drug which

Study: Medicare payments encourage overuse of risky anemia drug  -  Apr 17, 2007
WQAD,A new study finds that for-profit dialysis chains give higher doses of the drug Epogen than nonprofit dialysis centers. Some experts say that practice may

Amid Safety Questions  -  Apr 9, 2007
Wall Street Journal (subscription),The two anemia drugs, Epogen and Aranesp, account for almost half of Amgen's sales. Sales of Aranesp, the newer of the two, grew at a 27% pace in the fourth

Health Headlines For April 18, 2007  -  Apr 18, 2007
Central Florida News 13|,The report says Medicare reimburses dialysis centers for Epogen. Some for-profit chains negotiate discounts from the drug's maker, turning the medication

Shareholders sue Amgen over anti-anemia drugs  -  Apr 18, 2007
Providence Business News,During that period, the complaint says, the company marketed its anti-anemia drugs Epogen and Aranesp for “off-label� uses, and sold hundreds of thousands

Medicare Payments Encourage Overuse of Risky Anemia Drug on ...  -  Apr 18, 2007
Fox 28,The report finds that for-profit dialysis chains give higher dose of the drug Epogen than non-profit centers. The drug is approved by the FDA,

Study Heightens Concern Over Anemia Drugs  -  Apr 17, 2007
Wall Street Journal (subscription),Its anemia drugs Epogen and Aranesp are synthetic versions of the red-blood-cell boosting hormone erythropoietin. "We believe our dialysis organization

Market Place Amgen Seeks to Reverse Its Bad News  -  Apr 17, 2007
New York Times,Several recent studies suggest that its blockbuster anemia drugs, Aranesp and Epogen, might be harming patients, particularly if overused.

Amgen delays results release to include study data  -  Apr 11, 2007
MarketWatch...anemia franchise consists of Aranesp, which is currently approved to treat chemotherapy-induced anemia and chronic kidney disease-related anemia, and Epogen

Amgen Gets a Boost  -  Apr 19, 2007
Los Angeles Business Journal (subscription),Aranesp and its sister anemia drug, Epogen, are approved to treat anemia in people with kidney disease or undergoing chemotherapy.

Amgen Study Shows No Increased Aranesp Death Risk  -  Apr 19, 2007
Reuters.uk,Aranesp had sales of about $4.1 billion last year, and along with its predecessor Epogen accounted for roughly half of Amgen's sales. "This was the A No.

Amgen: Patience Could Be a Virtue  -  27 Mar 2007
Seeking Alpha,First, the FDA ordered the company to alter its warning label on Amgen's lead products for Anemia, Aronesp and Epogen, in order to warn doctors and patients

Complex generic biologics need more data: FDA  -  27 Mar 2007
Scientific American...as Genentech Inc.'s cancer drugs Herceptin and Avastin, as well as anemia drugs such as Amgen Inc.'s Epogen and Aranesp and Johnson & Johnson's Procrit.

AARP tells Congress to act on bio-generics  -  27 Mar 2007
United Press InternationalAccording to AARP, a brand-name drug for anemia, Epogen, can cost as much as $10000 per year and Cerezyne, for Gaucher's disease, can go as high as $200000

Makers of Aranesp, Epogen and Procrit: Stop Advertising  -  Mar 22, 2007
Lawyers and Settlements,Washington, DC: The manufacturers of Aranesp, Epogen and Procrit have been asked by Congress to stop advertising their popular anemia drugs to consumers.

FDA Warning Prompts Reconsideration of Medicare Reimbursement for ...  -  Mar 20, 2007
Kaiser network.org,Members of Congress and some physicians are pressuring Medicare to change its reimbursement policy for Amgen's Epogen after FDA earlier this month issued a

FDA warning drives doubts on Epogen drug  -  Mar 19, 2007
Boston Globe,Epogen combats anemia by raising red-blood counts in kidney patients. But Medicare has been under fire for allowing doses that exceed FDA-recommended limits

Levin, Papantonio and Mass Torts Made Perfect, Inc. Announce ...  -  Mar 13, 2007
PharmaLive.com (press release),..."We are excited to add Aranesp, Epogen and Procrit to the agenda of our upcoming seminar," said Michael B. Lynch, Esq., an attorney with Levin Papantonio

DaVita Inc. Shares Off on Epogen Warning Worry  -  Mar 12, 2007
Reuters.uk,Epogen in used in DaVita facilities to treat anemia caused by chronic kidney failure. DaVita runs about 1300 centers that perform dialysis, a procedure to

Revised Safety Information Approved for Aranesp, Epogen, and Procrit  -  Mar 13, 2007
Facts and Comparisons,The FDA has issued a public health advisory detailing new safety information for darbepoetin alfa (Aranesp) and epoetin alfa (Epogen and )

Amgen Announces Update To US Prescribing Information For Aranesp ...  -  Mar 12, 2007
Safety Online (press release),The indications for Aranesp and EPOGEN have not changed. Aranesp is indicated for the treatment of chemotherapy-induced anemia and anemia associated with

FDA - Black Box Warning on Anemia Drugs Epogen Procrit and Aranesp ...  -  Mar 12, 2007
Best Syndication,The drugs are Erythropoiesis-Stimulating Agents (ESAs) and include darbepoetin alfa (Aranesp) and epoetin alfa (Epogen and Procrit).

Amgen, DaVita shares off on Epogen worries  -  Mar 12, 2007
ReutersO: Quote, Profile , Research) Aranesp and Epogen, and Johnson & Johnson's (JNJ.N: Quote, Profile , Research) Procrit, advising doctors to choose the lowest

Amgen Under Fire From Congress  -  Mar 21, 2007
Forbes,Dingell asked Amgen to "cease all direct-to-consumer advertising and physician incentives" related to Epogen and Aranesp until the Food and Drug

Amgen's Trial Of Vectibix Falls Short; ImClone Shares Benefit  -  Mar 25, 2007
BioWorld Online,On the heels of a new warning label for its erythropoietin drugs Aranesp and Epogen, shares of Amgen Inc. dipped a little lower on more bad news.

Black Box Warning Ordered for Aranesp, Epogen, and Procrit  -  Mar 9, 2007
MedPage Today,Aranesp, Epogen, and Procrit and other erythropoiesis-stimulating agents increased the risk for death and for serious cardiovascular events when dosed to

Amgen (AMGN) Announces Update To US Prescribing Information for ...  -  Mar 9, 2007
StreetInsider.com (subscription),...a boxed warning in the prescribing information for the class of drugs known as Erythropoiesis-stimulating Agents (ESAs), including Aranesp and EPOGEN.

Prescribing Information for Aranesp(R) . and EPOGEN(R)  -  Mar 9, 2007
InfoBolsa,...for the class of drugs known as Erythropoiesis-stimulating Agents (ESAs), including Aranesp(R) (darbepoetin alfa) and EPOGEN(R) (Epoetin alfa).

Anaemia meds under review  -  Mar 23, 2007
Health24.com,The marketing and regulation of the commonly used anaemia drugs Epogen, Aranesp and Procrit are under review by a US Congressional committee.

Amgen, J&J told to stop drug ads  -  Mar 22, 2007
Los Angeles Times,The anemia drugs Aranesp and Epogen, made by Thousand Oaks-based Amgen, and Procrit, sold by New Brunswick, NJ-based Johnson & Johnson, have come under

Lawmakers Ask J&J and Amgen to Hold Off Promoting Top-Selling ...  -  Mar 23, 2007
CanadianBusiness.com,John Dingell and Bart Stupak, both of Michigan, issued letters late Wednesday requesting Amgen, which markets blockbusters Aranesp and Epogen,

Key Lawmaker Calls on Amgen to Halt 'Physician Incentives' for ...  -  Mar 21, 2007
Biologic Drug Report,Dingell, in his letter to Amgen CEO Kevin Sharer, expressed concern about reports that Amgen's Epogen and Aranesp biologics, "when used at higher than

Lawmakers Take Action on Anemia Drugs  -  Mar 22, 2007
Los Angeles Business Journal (subscription),Aranesp is Amgen's best-selling product, and when combined with Epogen, accounted for nearly half of the Thousand Oaks-based biotech’s revenue in 2006.

Anemia Drugs Under Review by Congress  -  Mar 22, 2007
Tuscaloosa News (subscription),The products — Epogen and Aranesp from Amgen and Procrit from Johnson & Johnson — are all forms of erythropoietin, or Epo, a protein made by the human

US House Committee Targets Anemia Drug Marketing  -  Mar 21, 2007
Reuters.uk,Amgen sells anemia drugs Epogen, for kidney disease patients, and Aranesp as a treatment for both kidney disease and cancer patients undergoing chemotherapy

Congressman to Amgen: Stop Advertising Anemia Drug  -  Mar 22, 2007
San Fernando Valley Business Journal Online (subscription),...sent a letter to Amgen CEO Kevin Sharer asking the company to “cease all direct-to-consumer advertising and physician incentives� for Epogen and Aranesp

Amgen, J&J told to stop drug ads  -  Mar 22, 2007
Therapeutics Daily (subscription) (press release),The anemia drugs Aranesp and Epogen, made by Thousand Oaks-based Amgen, and Procrit, sold by New Brunswick, NJ-based Johnson & Johnson, have

For Booming Biotech Firms, A New Threat: Generics  -  Mar 13, 2007
Wall Street Journal (subscription),Everyone agrees it's a lot harder to do so for a drug like Amgen's Epogen, a protein that boosts red blood cells, but generics companies say that thanks to

Amgen's, J&J's Anemia Drugs Get Stronger US Warning (Update4)  -  Mar 9, 2007
BloombergAranesp and Epogen together accounted for 47 percent of the company's revenue in 2006. Procrit, Johnson & Johnson's version of Epogen, had $3.18 billion in

FDA warns on anemia drugs after test deaths  -  Mar 9, 2007
Boston Globe,The "black box" warnings placed on the prescribing label for Amgen Inc.'s Epogen and Aranesp and Johnson & Johnson's Procrit are expected to result in more

FDA cracks down on Amgen  -  Mar 10, 2007
Ventura County Star (subscription),The US Food and Drug Administration announced Friday that it will include a warning on the prescribing information for the anemia drugs Procrit, Epogen and

Biotechnology and the Divine Right of Kings  -  Mar 15, 2007
Agoravox,When Johnson & Johnson ran into problems with its version of Epogen in Europe, it wasn’t caused by differences in the molecule.

Analysis: Payment System's Role in Overly Aggressive Use of ...  -  Mar 12, 2007
Biologic Drug Report,Epogen is used to treat anemia in some 1300 DaVita centers that perform dialysis, a procedure to filter waste from the blood of patients with kidney-disease

Generic biotechs may be on way  -  Feb 25, 2007
Chicago Tribune,Some of the drugs, like the anti-anemia drug Epogen, can cost more than $10000 a year per patient. Other biotech treatments for cancer, multiple sclerosis

FDA Warning Is Issued on Anemia Drugs’ Overuse  -  Mar 9, 2007
New York Times,The drugs are darbepoetin alfa, sold as Aranesp by Amgen, and epoetin alfa, sold as Epogen by Amgen and as Procrit by Johnson & Johnson.

New Flags for Amgen Drugs  -  Mar 9, 2007
Red Herring,Amgen, the world’s biggest biotech company, has built its business on anemia drugs like Epogen and experimental anemia drug Aranesp, which brought in more

Excessive use of Anemia Drugs could be Fatal - FDA  -  Mar 10, 2007
The Money Times,The popular drug brands under the threat are Aranesp, Epogen, made by Amgen Inc., and Procrit, sold by Johnson & Johnson, to treat patients undergoing

Cashing in on 'orphans'  -  Mar 16, 2007
CNNMoney.comAmgen (down $0.07 to $59.94, Charts) has Epogen, which started out as an orphan but is now used to treat anemia. With $2.5 billion in sales last year,

EPO Warning Nicks Amgen; Off-Label Risks Told Earlier  -  Mar 9, 2007
BioWorld Online,Amgen Inc. headed off worse damage from Friday's news of the "black box" label warning for the firm's flagship red-blood cell boosters Aranesp and Epogen by

Medicare Panel Urges Reimbursement Change to Help Curb Biologic Costs  -  Mar 2, 2007
Biologic Drug Report,The Medicare program currently spends about $2 billion a year providing Epogen to approximately 390000 Americans with end-stage kidney failure who are on

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional